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Abstract 
Farnesylated  prelamin  A  is  a  processing
intermediate produced in the lamin A matura-
tion pathway. Accumulation of a truncated far-
nesylated prelamin A form, called progerin, is a
hallmark of the severe premature ageing syn-
drome, Hutchinson-Gilford progeria. Progerin
elicits toxic effects in cells, leading to chro-
matin  damage  and  cellular  senescence  and
ultimately causes skin and endothelial defects,
bone resorption, lipodystrophy and accelerated
ageing. Knowledge of the mechanism underly-
ing  prelamin  A  turnover  is  critical  for  the
development  of  clinically  effective  protein
inhibitors that can avoid accumulation to toxic
levels without impairing lamin A/C expression,
which is essential for normal biological func-
tions. Little is known about specific molecules
that may target farnesylated prelamin A to elic-
it protein degradation. Here, we report the dis-
covery  of  rapamycin  as  a  novel  inhibitor  of
progerin,  which  dramatically  and  selectively
decreases protein levels through a mechanism
involving autophagic degradation. Rapamycin
treatment of progeria cells lowers progerin, as
well as wild-type prelamin A levels, and rescues
the  chromatin  phenotype  of  cultured  fibrob-
lasts, including histone methylation status and
BAF  and  LAP2a distribution  patterns.
Importantly,  rapamycin  treatment  does  not
affect lamin C protein levels, but increases the
relative expression of the prelamin A endopro-
tease ZMPSTE24. Thus, rapamycin, an antibi-
otic belonging to the class of macrolides, previ-
ously  found  to  increase  longevity  in  mouse
models,  can  serve  as  a  therapeutic  tool,  to
eliminate  progerin,  avoid  farnesylated
prelamin  A  accumulation,  and  restore  chro-
matin dynamics in progeroid laminopathies.
Introduction
Hutchinson-Gilford  progeria  syndrome
(HGPS) is an autosomal dominant condition
which develops in the first or second year of
life, followed by severe and rapid premature
senescence,  which  involves  almost  all  tis-
sues.1,2 Patients present delayed growth, short
stature, alopecia, thinning of skin, loss of sub-
cutaneous  fat,  midface  hypoplasia,  skeletal
involvement with osteolysis and fractures, pre-
mature atherosclerosis, cardiac failure leading
to death or stroke at about 13.5 years. A de
novo missense mutation in exon 11 leads to
creation of an abnormal splice donor site that
results in expression of a truncated, perma-
nently farnesylated prelamin A, termed prog-
erin.3,4 This is the most common mutation in
HGPS. Toxicity of progerin has been well docu-
mented in several papers.5-7 Lowering progerin
levels or eliminating its expression has been
shown  to  ameliorate  the  cellular  phenotype
both  in  mouse  and  human  cell  models.5,8
Moreover, accumulation of wild-type farnesy-
lated prelamin A as a secondary effect of prog-
erin expression, worsens the cellular pheno-
type.9-11 In the reported study, we explored the
possibility  that  rapamycin,  an  antibiotic
belonging to the class of macrolides, known to
activate autophagy in cells through inactiva-
tion of the inhibitory mTOR-dependent path-
way, could trigger progerin degradation.12 Our
results  show  that  rapamycin  treatment  of
HGPS  cells  dramatically  and  selectively
reduces  progerin  and  prelamin  A  levels  and
elicits rescue of LAP2a, BAF and trimethylated
H3K9 organisation, thus improving the chro-
matin epigenetic status.
Materials and Methods
Cell cultures and transfection
HGPS skin fibroblasts were obtained from a
6-year-old  patient  carrying  the  G608G  LMNA
mutation. Control skin fibroblast cultures were
obtained from skin biopsies of healthy patients
(mean age 12) undergoing orthopaedic surgery,
following a written consent. The protocol had
been approved by the local ethical committee
and informed consent had been obtained from
patients  or  families.  Cell  cultures  had  been
established and cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal
calf serum (FCS) and antibiotics. The experi-
ments  were  performed  at  passages  5-10.
Transient transfections of HEK 293T cells were
performed by calcium phosphate method. FLAG-
tagged plasmids contained wild-type prelamin A
(LA-WT) or prelamin A ʔ50 (LA-ʔ50), encoding
a form devoid of the 50 aminoacids lacking in
the  progerin  sequence.11 After  transfection,
cells were incubated for 72 h.
Drug treatments 
Rapamycin (1 ʼM, Sigma, Milano, Italy) was
applied to cultured fibroblasts  for 6 days. This
drug inhibits mTOR activity and releases the
autophagic signaling pathway, which is inhib-
ited by mTOR.13 In transfected HEK 293 cells,
rapamycin was applied at 2 ʼM concentration
for 72 h. To block lysosomal activity, chloro-
quine (Sigma, 25 ʼM for 10 h) was applied
either in the presence or in the absence of
rapamycin.  To  check  proteasome-mediated
degradation the ubiquitin proteasome inhbitor
MG132 (1 ʼM for 10 h) was applied. 
Antibodies 
Antibodies employed for Western blot analy-
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sis  or  immunofluorescence  labeling  were:
anti-lamin A/C, goat polyclonal (SC-6215, used
at 1:1000 dilution for the Western blot analysis,
Santa  Cruz  Biotechnology  Inc.,  Segrate,  MI,
Italy);  anti-prelamin  A,  goat  polyclonal  (SC-
6214 used at 1:100 dilution for the immunoflu-
orescence analysis, Santa Cruz); anti-prelamin
A,  rabbit  polyclonal  (antibody  1188-2,
Diatheva, Fano, Italy), raised against the last
15  aminoacids  of  the  prelamin  A  sequence
including the farnesylated cysteine residue but
not  the  SIM  sequence;14 anti-LAP2a,  rabbit
polyclonal;15 anti-trimethyl-H3K9,  rabbit  poly-
clonal (Upstate, Lake Placid, NY, USA); anti-
emerin, mouse monoclonal (Monosan, Uden,
The Netherlands); anti-BAF, rabbit polyclonal
(FL-89, Santa Cruz); anti-LC3 rabbit polyclonal
antibody  (ABR,  Pierce);  anti-FLAG,  mouse
monoclonal (M2, Sigma); anti-actin, goat poly-
clonal (Santa Cruz).
Western blot analysis
Western blot analysis was done as follows.
Cells were lysed in lysis buffer containing 20
mM Tris-HCl, pH 7.0, 1% Nonidet P-40, 150 mM
NaCl, 10% glycerol, 10 mM EDTA, 20 mM sodi-
um fluoride, 5 mM sodium pyrophosphate, 1
mM Na3VO4, 1 mM PMSF, 10 ʼg/mL leupeptin
and  10  ʼg/ml  pepstatin  at  4°C.  Cell  lysates
were diluted in Laemmli buffer, subjected to
SDS-PAGE (8%) and transferred to nitrocellu-
lose  membrane.  Membranes  were  saturated
with 4% BSA and incubated with primary anti-
bodies for 1 h at room temperature. Secondary
antibodies were used at 1:10000 dilution for 30
min. Immunoblotted bands were revealed by
the Amersham ECL detection system. Intensity
measurement was performed using a BioRad
densitometer (GS 800) equipped with Quantity
One Software.
Gene expression analysis
Total RNA was isolated using Rneasy Mini
Kit  (Qiagen  GmbH,  Hilden,  Germany)  from
confluent fibroblast cultures following manu-
facturer instructions. RNA was reverse tran-
scribed  into  cDNA  using  the  High  Capacity
cDNA  Reverse  Transcription  Kit  (Applied
Biosystems, Monza, Italy). LMNA or ZMPSTE24
expression was evaluated by Real Time PCR,
performed  using  an  Applied  Biosystems
StepOne  termal  cycler  instrumentation
(Applied Biosystems), by amplifying 1 ʼg of
cDNA and the TaqMan Gene Expression Assays
(Applied  Biosystems).  Probes  and  primers
obtained by Applied Biosystems were: GAPDH,
assay  ID  Hs99999905_m1,  LMNA,  assay  ID
Hs00153462_m1*,  ZMPSTE24,  assay  ID
Hs00195298_m1*. The amplification protocol
was: 50°C for 2 min; 95°C for 10 min; 95°C for
15 s, 60°C for 1 min, for 40 cycles. The results
were calculated by the 2 ʔʔ-CT method16 or as
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Figure 1. Rapamycin reduces progerin level in HGPS cells. A) Western blotting evaluation
of lamin A/C and progerin in control (CONTROL) and Hutchinson Gilford progeria
cells (HGPS). Whole lysates from control and HGPS cells untreated (-) or treated (+) with
rapamycin (Rapamycin), MG132 or chloroquine-diphosphate (Cq) were subjected to
lamin A/C, LC3-B2 and actin antibodies detection; B) densitometric analysis of lamin A
and C immunolabeled bands detected in control fibroblasts; C) densitometric analysis of
lamin A and C immunolabeled bands detected in HGPS fibroblasts; P=0.0358 for lamin
A (rapa), P=0.0298 for lamin A (Mg); D) densitometric analysis of progerin immunoblot-
ted bands; P=0.0390 for progerin (rapa); P=0.0458 for progerin (Mg); E) prelamin A,
FLAG and LC3-B2 protein levels evaluation in HEK-293 cells expressing FLAG-tagged
wild type prelamin A (LA-WT) or progerin (LA-ʔ50). Immunolabeled bands observed in
untreated (-) or rapamycin (Rapamycin) and chloroquine-diphosphate (Cq) treated (+)
cells are shown; F) densitometric of FLAG immunoblotted bands; G) RT-PCR analysis of
ZMPSTE24  and  LMNA  mRNA  expression  in  untreated  (Nt)  and  rapamycin-treated
HGPS cells (Rapa) and control (control); 2 -ʔʔCT values are reported relative to untreated
control samples. P=0.0236 for LA-ʔ50 (rapa); H) ratio between ZMPSTE24 and LMNA
mRNA expression. Values are means of duplicate experiments ﾱ S.D. In B, C, D and F
densitometric analysis of triplicate experiments was performed, and the mean values ﾱ
S.D. are reported; asterisk indicates statistically significant difference with respect to
lamin A or progerin densitometry in untreated samples; statistical significance was calcu-
lated by the Mann-Whitney test vs untreated HGPS samples, or cells expressing LMNA
constructs. [page 202] [European Journal of Histochemistry 2011; 55:e36]
ratio between gene of interest and GAPDH ref-
erence  gene.17 The  experiments  were  per-
formed in duplicate. 
Immunofluorescence 
Human fibroblasts grown on coverslips were
fixed with 4% paraformaldehyde at 4°C for 10
min and permeabilized with 0.15% Triton X-
100 for 5 min. Alternatively, cells were fixed
with  absolute  methanol  at  -20°C.  Samples
were incubated with PBS containing 4% BSA
to saturate non-specific binding and incubated
with primary antibodies overnight at 4°C, and
with secondary antibodies for 1 h at room tem-
perature. Anti-prelamin A Sc-6214, anti-lamin
A/C  and  anti-trimethyl  H3K9  were  used  at
1:100  dilution.  Anti-prelamin  A  1188-2  and
anti-BAF were applied at 1:10 dilution. Anti-
LAP2a was  applied  at  1:300  dilution.  Slides
were  mounted  with  an  anti-fade  reagent  in
glycerol and observed with a Nikon E 600 fluo-
rescence microscope equipped with a digital
camera. 
Statistical analysis
Statistical analysis was performed using the
non-parametric  Mann-Whitney  U  test.18
Experiments were done in triplicate and differ-
ences were considered statistically significant
for P<0.05.
Results
Rapamycin treatment of HGPS
fibroblasts 
In order to test rapamycin effect on prelamin
A  in  laminopathic  cells,  we  treated  cultured
fibroblasts with rapamycin for 6 days. HGPS
nuclei  accumulate  the  truncated  prelamin  A
form, known as progerin, obtained by aberrant
splicing of the LMNA gene due to the G608G
mutation. In HGPS cells, progerin levels were
strikingly reduced following administration of
rapamycin  (Figure  1A).  Progerin  was  not
degraded under basal conditions, as shown by
absence of CQ or MG132-induced protein accu-
mulation, showing that the protein minimally
undergoes spontaneous degradation (Figure 1
A-D). 
Transfection of HEK293 cells with an LMNA
construct  encoding  progerin  (LA-ʔ50)  was
performed to support the above reported data
(Figure  1E).  Rapamycin  treatment  for  72  h
strongly  reduced  LA-ʔ50  level,  while  CQ
administration did not cause protein accumu-
lation (Figure 1E), supporting the finding that
progerin  does  not  undergo  degradation  in
untreated cells. Quantitative analysis also sup-
ported the results showing progerin degrada-
tion by rapamycin (Figure 1 D,F). Importantly,
accumulation of LC3-B2, which is a marker of
autophagic  activity,  was  observed  in  HGPS
cells and, to a lower extent, in HEK293 cells
expressing  progerin,  before  rapamycin  trea-
ment, but was increased by rapamycin treat-
ment (Figure 1 A,E). The latter finding sug-
gested that activation of the authophagic sig-
naling is triggered by progerin itself.
RT-PCR  analysis  of  LMNA or  ZMPSTE24
mRNA was performed in HGPS before and after
rapamycin  treatment.  LMNA and  ZMPSTE24
expression were not decreased by rapamycin
treatment, demonstrating that progerin elimi-
nation does not occur through downregulation
of mRNA expression (Figure 1G). Figure 1H
shows that the ratio between ZMPSTE24 and
LMNA expression is increased following treat-
ment, suggesting that not only degradation of
progerin,  but  also  processing  of  wild-type
prelamin A is potentially  increased by drug
treatment.
Nuclear envelope in rapamycin
treated cells 
To test whether rapamycin could affect other
nuclear  envelope  constituents,  besides
prelamin A, control and HGPS cells were exam-
ined before and after drug treatment. Figure 2
shows the western immunoblot of lamin B1,
lamin B2, emerin, BAF and LAP2a (Figure 2A).
Rapamycin  treatment  did  not  affect  protein
levels  in  control  or  laminopathic  fibroblasts
(Figure  2A).  However,  in  HGPS  fibroblasts,
where LAP2a was downregulated, rapamycin
administration restored protein levels compa-
rable to controls (Figure 2 A,B). These results
suggested that reduction of progerin and pos-
sibly wild-type prelamin A levels could restore
nuclear integrity in HGPS cells. 
Progerin and chromatin-binding
proteins in rapamycin-treated cells
To support this hypothesis, progerin,  farne-
sylated  prelamin  A  and  chromatin-binding
prelamin  A  partners  were  examined  by
immunofluorescence  before  and  after
rapamycin treatment (Figure 2 C-H). Progerin
and farnesylated prelamin A were detected at
the nuclear rim of HGPS fibroblasts, but not in
controls (Figure 2 C-F). Rapamycin dramati-
cally  reduced  progerin  and  farnesylated
prelamin A levels (Figure 2 D-F).  Importantly,
rapamycin treatment did not modify lamin A/C
level  and  localization,  thus  confirming  that
lamin  C  is  not  substantially  affected  by
rapamycin (Figure 2 E,F). Next, the expression
pattern  of  the  prelamin  A-binding  protein
LAP2a was examined. LAP2a was evenly dis-
tributed in the nucleoplasm of control fibrob-
lasts,  but  was  mislocalized  to  the  nuclear
periphery in HGPS fibroblasts (Figure 2 C,D).
Rapamycin restored both LAP2a level (Figure
2 A,B) and the proper distribution of LAP2a
throughout the nucleoplasm (Figure 2 C,D).
Next, the effect of rapamycin treatment on the
localization of the prelamin A and chromatin-
binding protein BAF, was assessed. BAF was
recruited to the nuclear envelope in lamino-
pathic cells,11 while in a major proportion of
control cells it was located in the cytoplasm
and, to a lower amount in the nucleus (Figure
2  G,H).  Treatment  with  rapamycin,  restored
the proper distribution of BAF in HGPS cells
(Figure 2 H).  
Chromatin organization is 
recovered in rapamycin treated
laminopathic cells 
The above reported recovery of LAP2a and
BAF  expression  patterns  obtained  by
rapamycin  treatment,  suggested  that  loss  of
heterochromatin, which is known to occur in
HGPS cells could have been similarly rescued.
The methylation status of histone H3 lysine 9
(H3K9) was determined by specific labeling of
the trimenthylated lysine. We had previously
shown altered methylation pattern of H3K9 in
HGPS cells.5Here, we could observe recovery of
trimethyl-  H3K9  distribution  pattern  in
rapamycin-treated  HGPS  nuclei  (Figure  3).
Fluorescence intensity measurement showed
that trimethylated H3K9 levels were strongly
reduced in HGPS nuclei; morevover, the clus-
tered distribution of the histone observed in
control cells (Figure 3 A,B) was completely lost
(Figure 3 C,D). Trimethyl-H3K9 was not affect-
ed  by  rapamycin  treatment  in  control  cells
(Figure 3 E,F). However, the proper organiza-
tion  and  expression  level  of  trimethyl-H3K9
was restored by rapamycin treatment of HGPS
cells (Figure 3 G,H,I), which indicated recovery
of  heterochromatin  organization.  Thus,  we
conclude  that  rapamycin  may  be  effectively
used  to  restore  the  chromatin  phenotype  in
lamino  pathies.
Discussion
The study here reported shows that activa-
tion  of  the  mTOR-dependent  authophagic
pathway using rapamycin can counteract prog-
erin and farnesylated prelamin A accumulation
in HGPS cells, leading to rescue of the chro-
matin phenotype of senescent cells. 
The toxicity of farnesylated prelamin A and
progerin  is  well  established.5,14,19-21 Several
studies have shown that reduction of prelamin
A  or  progerin  levels  either  by  molecular
approaches6,8 or by drug treatment5,21 improves
the cellular phenotype in progeroid cells. Here,
we used a well-known drug, rapamycin, which
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Figure 2. Nuclear envelope/lamina proteins in rapamycin treated cells. A) Western Blotting analysis of LAP2a (LAP2￿), lamin B1 (lamin
B1), lamin B2 (lamin B2), emerin (emerin) and Barrier-to-autointegration factor (BAF) in control (control) and HGPS cells (HGPS)
untreated (-) or treated (+) with rapamycin. Actin was detected as protein loading control. Immunolabeled bands are shown; B) densit-
ometric analysis of LAP2a immunolabeled bands detected in Western blotting analysis performed in control and HGPS untreated (-)
or rapamycin treated cells (+). Asterisk indicates statistically significant difference, P=0.0319 for HGPS + rapamycin (+) vs untreated
HGPS (-); C) prelamin A and LAP2a immunofluorescence labeling performed in untreated (-) or rapamycin  treated (+) control cells.
Prelamin A was evaluated using a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody (red). LAP2a distri-
bution was evaluated using a rabbit-polyclonal antibody visualized by FITC-conjugated secondary antibody (green); D) progerin and
LAP2a immunolabeling detection performed in untreated (-) or rapamycin treated (+) HGPS cells. Progerin (progerin) detection was
performed using a mouse-monoclonal antibody visualized by Cy3-conjugated secondary antibody (red). LAP2a distribution was eval-
uated using a rabbit-polyclonal antibody visualized by FITC-conjugated secondary antibody (green). In untreated HGPS cells progerin
staining was observed, while LAP2a labeling was decreased. Rapamycin treatment dramatically reduced progerin labeling and restored
LAP2 a staining levels; E) Lamin A/C and farnesylated-prelamin A detection performed in untreated (-) or rapamycin treated (+) con-
trol cells. Lamin A/C  (lamin A/C) was evaluated using a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody
(red). Farnesylated-prelamin A  (F-prelamin A) staining was performed using a rabbit-polyclonal antibody visualized by FITC-conjugat-
ed secondary antibody (green). Lamin A/C was detected in untreated or treated cells at the same levels. F-prelamin A was  undetected in
both samples; F) Lamin A/C and farnesylated-prelamin A detection performed in untreated (-) or rapamycin treated (+) HGPS cells.
Lamin A/C (lamin A/C) was evaluated using a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody (red).
Farnesylated-prelamin A  (F-prelamin A) staining was performed using a rabbit-polyclonal antibody visualized by FITC-conjugated sec-
ondary antibody (green). Lamin A/C staining was observed at the nuclear lamina of both untreated and treated cells. F-prelamin A stain-
ing observed in untreated cells was strongly reduced by rapamycin treatment; G) prelamin A BAF detection performed in untreated (-)
or rapamycin treated (+) control cells. Prelamin A was stained by a goat-polyclonal antibody visualized by TRITC-conjugated second-
ary antibody (red). BAF immunolabeling detection was performed by a rabbit-polyclonal antibody visualized by FITC-conjugated sec-
ondary antibody (green). Prelamin A was undetectable in untreated or rapamycin treated cells. BAF showed a normal cellular distribu-
tion in both samples; H) prelamin A and Barrier-to-autointegration (BAF) detection was performed in untreated (-) or rapamycin treat-
ed (+) HGPS cells. Prelamin A was stained by a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody (red).
BAF was labeled by rabbit-polyclonal antibody and visualized by FITC-conjugated secondary antibody (green). Prelamin A staining was
present at the nuclear lamina of untreated cells while in rapamycin treated cells lamin A precursor was undetectable. BAF nuclear local-
ization was observed in HGPS untreated cells. The normal BAF nucleo-cytoplasmic cellular distribution was recovered by rapamycin
treatment. In panel C, D, E, F,G and H nuclei were counterstained with DAPI. Scale bar, 10 ﾵm.[page 204] [European Journal of Histochemistry 2011; 55:e36]
interferes  with  m-TOR  inhibition  of
autophagy,  thus  triggering  the  authophagic
pathway.13 Authophagy  is  a  physiological
degradation mechanism, mostly aimed at scav-
enging damaged organelles, but also implied
in the elimination of altered proteins.13 Our
results show a major role of lysosomal degrada-
tion in the reduction of prelamin A levels trig-
gered by rapamycin, as demonstrated by the
effective accumulation of progerin, following
cloroquine  inhibition  of  rapamycin-treated
cells.  Moreover, our study shows that degrada-
tion of progerin does not occur at detectable
levels in untreated cells. Thus, toxicity of prog-
erin, which is likely associated with aberrant
intermolecular  interactions  mediated  by  the
farnesylated C-terminus of the molecule,11,22 is
further increased by the resistance to degrada-
tion of that prelamin A form. 
In this scenario, the availability of a drug
capable of triggering farnesylated prelamin A
degradation paves the way to promising thera-
peutic perspectives. Activation of authophagy
by prelamin A accumulation has been report-
ed23 and it is supported by our evidence of LC3-
B2 accumulation24 in untreated HGPS cells, as
well  as  by  electron  microscopy  studies  (not
shown). However, since progerin is not or min-
imally degraded in untreated HGPS fibroblasts,
while undergoes degradation upon rapamycin
stimulus,  we  suggest  that  the  function  of
rapamycin  in  laminopathic  cells  is  to  target
progerin  and  farnesylated  prelamin  A  to
degrading enzymes. This event could be medi-
ated  by  the  prelamin  A-specific  C-terminus,
since lamin C appears to be substantially unaf-
fected by drug treatment. In this context, we
speculate that a physiological role of prelamin
A processing could be to provide a pool of far-
nesylated  lamin  A  precursors  to  be  either
degraded  or  processed  to  mature  protein,
depending on the cell requirement. The unex-
pected  finding  that  the  relative  amount  of
ZMPSTE  mRNA  is  increased  in  rapamycin-
treated cells, suggests that not only prelamin A
degradation,  but  also  prelamin  A  processing
may be enhanced by drug treatment. In this
context, the restoring ability of rapamycin we
describe in HGPS may be extended to the treat-
ment of other laminopathies featuring accu-
mulation of farnesylated prelamin A forms dif-
ferent from progerin.
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Figure 3. Rapamycin treatment rescues the heterochromatin marker trimethyl-H3K9 in
HGPS cells. Immunofluorescence labeling of trimethyl-H3K9 (H3K9) in control and
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